A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2002
10/17/2002	US20020151588 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
10/17/2002	US20020151586 Antidiabetic agents
10/17/2002	US20020151576 Inhibiting sodium/hydrogen exchanger activity and the n-type calcium channel with imidazoline derivatives
10/17/2002	US20020151572 Nitric oxide synthase (NOS); alone or in combination with another active agent for the treatment of psoriasis, an antiinflammatory, an analgesic, a cognition enhancer or sleep disorder treatment
10/17/2002	US20020151565 Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders
10/17/2002	US20020151563 Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
10/17/2002	US20020151560 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
10/17/2002	US20020151559 Analgesic combination of oxycodone and 6-MNA
10/17/2002	US20020151551 Use of growth hormone secretagogues in conjunction with physical exercise cross reference to related application
10/17/2002	US20020151545 Anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and metastasis inhibitors in treating cancer
10/17/2002	US20020151541 For treatment of respiratory tract diseases
10/17/2002	US20020151536 Substituted azetidinone is used as sterol absorption inhibitor and a fibric acid derivative selected from fenofibrate, clofibrate, gemfibrozil, ciprofibrate, bezafibrate, clinofibrate etc
10/17/2002	US20020151531 Administering to a female of child bearing age over a period of 28 consecutive days a first phase of from 18 to 21 daily dosage units of a progestational agent, and a second phase of from 1 to 7 daily dosage units of an antiprogestin agent
10/17/2002	US20020151521 Packaged condomes containing spermicides, microbiocides and viricides, an acid buffer solution, a wound healing and diffusion impedance compound selected from dextran sulfate, chondroitin sulfate, pentosan polysulfate and a hyaluronate
10/17/2002	US20020151508 Administering therapeutically effective amount of liposomal anthracycline composition in association with therapeutically effective amount of antibody directed against extracellular domain of growth factor receptor
10/17/2002	US20020151506 Catechins for the treatment of fibrillogenesis in Alzheimer's disease, Parkinson's disease, systemic AA amyloidosis, and other amyloid disorders
10/17/2002	US20020151505 Treatment of helicobacter with isothiocyanates
10/17/2002	US20020151504 Amino acid containing compounds useful as modulators of the immune system
10/17/2002	US20020151503 Methods of cancer treatment using naaladase inhibitors
10/17/2002	US20020151501 Compounds having growth hormone releasing activity
10/17/2002	US20020151498 Medicaments that modify activity of Lipolysis Stimulated Receptor and that can be used to influence partitioning of dietary lipids between liver and peripheral tissues, including adipose tissue
10/17/2002	US20020151488 G-CSF analog compositions and methods
10/17/2002	US20020151480 Identifying a compound to treat a cardiovascular disease, e.g., atherosclerosis, characterized by aberrant 10218 nucleic acid activity or expression; detecting the presence of a nucleic acid in the sample that hybridizes to the probe
10/17/2002	US20020151478 Fusion protein comprising a latency associated peptide and a proteolytic cleavage site wherein the fusion protein is associated with a pharmaceutically active agent; gene therapy; genetic engineering; antiinflammatory agents
10/17/2002	US20020151464 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
10/17/2002	US20020151460 Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
10/17/2002	US20020151459 Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase
10/17/2002	US20020151070 Lipid compounds and compositions containing them which can be used for the transfer of at least one active substance, in particular a polynucleotide, into a target cell and use in gene therapy
10/17/2002	US20020151022 Kinase capable of site-specific phosphorylation of IkappaBalpha
10/17/2002	US20020151021 Stimulus-inducible protein kinase complex and methods of use therefor
10/17/2002	US20020151015 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
10/17/2002	US20020150984 Peptides for activation and inhibition of deltaPKC
10/17/2002	US20020150963 Map
10/17/2002	US20020150958 Detecting modulator of inflammation; obtain enzyme sample, incubate with modulator, monitor adjustment in enzyme activity, adjustment in activity indicate modulator
10/17/2002	US20020150953 Detecting modulators of muscle protein activity; obtain mixture of calcineurin and muscle protein, monitor binding, incubate with modulator, monitor adjustment in binding activity compare to control
10/17/2002	US20020150888 Methods of screening for modulators of HIV infection
10/17/2002	US20020150632 Psychonutracological method for craving reduction in humans
10/17/2002	US20020150631 Methods of treating prion disease in mammals
10/17/2002	US20020150630 Zinc chloride composition, unit dose packaging, applicator, and method of use in treating cancer and other skin diseases
10/17/2002	US20020150624 Mixture of drug, aminoacrylate polymer and acid
10/17/2002	US20020150619 Erythromyacin antibiotic product, use and formulation thereof
10/17/2002	US20020150617 Free of excipients; compaction
10/17/2002	US20020150565 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/17/2002	US20020150561 Cell proliferation; culture product
10/17/2002	DE10164711A1 Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren und/oder Aminosäureanalogen zur Modulation des Glycolyse-Enzym-Komplexes, des Malat Aspartat Shuttles und/oder der Transaminasen Use of sugar phosphates, sugar phosphate analogs, amino acids and / or amino acid analogs to modulate the glycolytic enzyme complex, the malate aspartate shuttle and / or the transaminases
10/17/2002	DE10118306A1 Composition for intranasal administration of imidazo-triazinone derivative cGMP PDE inhibitor for treatment of erectile dysfunction, also containing local anesthetic to prevent nasal blockage and improve absorption
10/17/2002	DE10118305A1 Composition for intranasal administration of cGMP PDE inhibitor for treatment of erectile dysfunction, also containing local anesthetic to prevent nasal blockage and improve absorption
10/17/2002	CA2446886A1 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
10/17/2002	CA2443378A1 Methods of screening and using inhibitors of angiogenesis
10/17/2002	CA2443334A1 Protein modification and maintenance molecules
10/17/2002	CA2443294A1 Remedies for infant chronic arthritis-relating diseases
10/17/2002	CA2443025A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002	CA2442849A1 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
10/17/2002	CA2442817A1 Implantation serine proteinases
10/17/2002	CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002	CA2442530A1 Compounds and methods for inhibiting mrp1
10/17/2002	CA2442141A1 Compounds and pharmaceutical compositions for inhibiting mrp1
10/17/2002	CA2442092A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002	CA2441638A1 Experimental animals for evaluation of therapeutic effects on corneal epithelial damages
10/17/2002	CA2441442A1 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	CA2440196A1 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
10/16/2002	EP1249238A2 Topical pharmaceutical composition comprising betanechol
10/16/2002	EP1249229A2 Sustained delivery of an active agent using an implantable system
10/16/2002	EP1249160A1 Model animal with favorite onset of rheumatoid arthritis
10/16/2002	EP1248847A1 Irak-4: compositions and methods of use
10/16/2002	EP1248842A1 2871 receptor, a g-protein coupled receptor and methods of use thereof
10/16/2002	EP1248837A2 Angiotensin converting enzyme homolog and its use
10/16/2002	EP1248835A2 Genetically modified fibroblast cell
10/16/2002	EP1248830A1 Antimicrobial compositions
10/16/2002	EP1248802A2 Soluble ctla4 mutant molecules and uses thereof
10/16/2002	EP1248792A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression
10/16/2002	EP1248782A1 Anticancer compound and enantiomer separation method useful for synthesizing said compound
10/16/2002	EP1248781A1 Pyrazole cyclic amp-specific pde inhibitors
10/16/2002	EP1248768A1 Bile acid-substituted phenyl-alkenoylguanidines, method for producing said phenyl-alkenoylguanidines, use thereof as medicaments or diagnostic reagents and medicaments containing the same
10/16/2002	EP1248654A2 Intra-tumoral administration of il-12 encoding nucleic acid molecules
10/16/2002	EP1248651A1 Product comprising a heterotrimeric g protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension
10/16/2002	EP1248636A1 Dextrin containing compositions for prevention of adhesions
10/16/2002	EP1248632A2 Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
10/16/2002	EP1248630A1 Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method
10/16/2002	EP1248629A1 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
10/16/2002	EP1248628A1 Phospholipid compositions as anti-inflammation agents
10/16/2002	EP1248626A2 Pharmaceutical compositions containing steroidal structures and uses thereof
10/16/2002	EP1248625A2 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
10/16/2002	EP1248623A2 Treatment of diabetic ulcers
10/16/2002	EP1248613A1 Clonidine preparations
10/16/2002	EP1248609A1 Method of treating benign forgetfulness
10/16/2002	EP1248604A2 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
10/16/2002	EP1248602A2 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
10/16/2002	EP1248601A1 Control of microbial populations in the gastrointestinal tract of animals
10/16/2002	EP1140065A4 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
10/16/2002	EP1100528B1 Use of novel agents inducing cell death in synergy with interferons
10/16/2002	EP0973794B1 Netrin receptors
10/16/2002	EP0941108B1 Wound healing and treatment of fibrosis
10/16/2002	EP0914147B1 Atrial natriuretic peptide (anp) as an additive to peritoneal dialysis solutions
10/16/2002	EP0877605B1 Solid instant-release forms of administration and process for producing the same
10/16/2002	EP0831826B1 Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
10/16/2002	EP0812193B1 Pharmaceutical compositions containing a benzydamine or its salt and an antimicrobial agent
10/16/2002	EP0808168B1 Pharmaceutical composition for the treatment of herpes
10/16/2002	EP0802731B1 Prophylactic treatment of allergic contact dermatitis

1 ... 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 ... 1151